Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

[1]  S.W.B. Newsom,et al.  Tuberculosis. Clinical diagnosis and management of tuberculosis and measures for its prevention and control , 2006 .

[2]  M. Tamm,et al.  Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. , 2012, Proceedings of the American Thoracic Society.

[3]  B. Metchock,et al.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[4]  P. Barnes,et al.  Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. , 2005, American journal of respiratory and critical care medicine.

[5]  L. Fabbri,et al.  Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. , 2005, American journal of respiratory and critical care medicine.

[6]  G. Enders,et al.  Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[7]  Catherine D DeAngelis,et al.  Tuberculosis--a global problem requiring a global solution. , 2005, JAMA.

[8]  J. Yim,et al.  Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. , 2005, JAMA.

[9]  P. Francioli,et al.  Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Tanoue,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. , 2005, American journal of respiratory and critical care medicine.

[11]  M. Pai,et al.  Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review , 2004 .

[12]  L. Fabbri,et al.  T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. , 2004, American journal of respiratory and critical care medicine.

[13]  P. Barnes.  Diagnosing latent tuberculosis infection: turning glitter to gold. , 2004, American journal of respiratory and critical care medicine.

[14]  Y. Sasaki,et al.  Specific Detection of Tuberculosis Infection: An Interferon-γ–based Assay Using New Antigens , 2004 .

[15]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[16]  M. Pai,et al.  Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. , 2004, The Lancet. Infectious diseases.

[17]  J. Deeks,et al.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak , 2003, The Lancet.

[18]  D. Holt,et al.  Congenital Tuberculosis and Management of Exposures in a Neonatal Intensive Care Unit , 2002, Infection Control & Hospital Epidemiology.

[19]  T. Eguale,et al.  Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients , 2002, Journal of Clinical Microbiology.

[20]  J. Deeks,et al.  Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells , 2001, The Lancet.

[21]  R. Wilkinson,et al.  Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. , 2001, American journal of respiratory and critical care medicine.

[22]  P. Barnes.  Diagnosing latent tuberculosis infection: the 100-year upgrade. , 2001, American journal of respiratory and critical care medicine.

[23]  R. O'brien,et al.  Tuberculosis elimination: are we willing to pay the price? , 2001, American journal of respiratory and critical care medicine.

[24]  L. Geiter,et al.  Ending Neglect: The Elimination of Tuberculosis in the United States , 2000 .

[25]  M. Vjecha,et al.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. , 1997, The New England journal of medicine.

[26]  Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention. , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[27]  R. Huebner,et al.  The tuberculin skin test. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  T. Anane,et al.  Diagnosis of tuberculosis in children. , 1992, Children in the tropics.

[29]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[30]  Ferebee Sh.  Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970 .

[31]  S. Ferebee.  Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970, Bibliotheca tuberculosea.